Along with “Remission Possible,” one of the new taglines on the redesigned EpicentRx website is “Enter the Epicenter.”
Which makes sense – at least to us – on at least two levels.
Firstly, epicenter means “dead center,” which EpicentRx lead therapy, RRx-001 (nibrozetone), takes literally since it is associated with tumor necrosis and highly immunogenic cell death at the core or center of solid tumors, as shown below. ICD gooses the dysfunctional immune system with the release of antigens and danger signals from the damaged/dying cells and puts it “hot on the scent” of the tumors, wherever they are, like a bloodhound.
Secondly, epicenter literally describes the point above the site of an earthquake. EpicentRx hopes to trigger an earthquake of disruptive innovation across the biopharmaceutical industry with its novel therapies, RRx-001 (nibrozetone) and AdAPT-001.
If approved, we really and truly believe – biased though we undoubtedly are – that these therapies will radically change and improve the treatment of several conditions such as cancer, neurodegenerative diseases, cardiovascular diseases, pulmonary hypertension, and endometriosis, resulting in positive aftershocks across the world for years to come.